2015
DOI: 10.1161/circulationaha.114.014021
|View full text |Cite
|
Sign up to set email alerts
|

Multimodality Imaging of Giant Right Coronary Aneurysm and Postsurgical Coronary Artery Inflammation

Abstract: A 52-year-old former recreational marathon runner with a history of permanent atrial fibrillation was referred to our institution because of fatigue and shortness of breath. His 12-lead ECG indicated atrial fibrillation with incomplete right bundle-branch block and inferolateral T-wave inversions ( Figure 1). The chest x-ray showed an abnormal structure with a circular silhouette at the projection of the right atrium in the anterior-posterior view (Figure 2). Transthoracic echocardiography revealed a vascular … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
5
0

Year Published

2016
2016
2018
2018

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(5 citation statements)
references
References 6 publications
0
5
0
Order By: Relevance
“…In October 1999, a new class III antiarrhythmic drug, dofetilide, was approved for treatment of atrial fibrillation in the United States (Pfizer, 2011). Atrial fibrillation, the most common sustained cardiac arrhythmia, affects more than 6 million people in the United States (American Heart Association, 2015) and 33 million worldwide (Chugh, Havmoeller, Narayanan, Singh, Rienstra, Benjamin, Gillum, Kim, McAnulty, Zheng, Forouzanfar, Naghavi, Mensah, Ezzati, and Murray, 2014). Dofetilide cardioverts persistent atrial fibrillation to sinus rhythm by selectively blocking the rapid delayed rectifier potassium current, which slows the efflux of potassium ions, reduces the repolarization rate of the cell, and widens the plateau of the action potential (Mirams, Cui, Sher, Fink, Cooper, Heath, McMahon, Gavaghan, and Noble, 2011).…”
Section: Introductionmentioning
confidence: 99%
“…In October 1999, a new class III antiarrhythmic drug, dofetilide, was approved for treatment of atrial fibrillation in the United States (Pfizer, 2011). Atrial fibrillation, the most common sustained cardiac arrhythmia, affects more than 6 million people in the United States (American Heart Association, 2015) and 33 million worldwide (Chugh, Havmoeller, Narayanan, Singh, Rienstra, Benjamin, Gillum, Kim, McAnulty, Zheng, Forouzanfar, Naghavi, Mensah, Ezzati, and Murray, 2014). Dofetilide cardioverts persistent atrial fibrillation to sinus rhythm by selectively blocking the rapid delayed rectifier potassium current, which slows the efflux of potassium ions, reduces the repolarization rate of the cell, and widens the plateau of the action potential (Mirams, Cui, Sher, Fink, Cooper, Heath, McMahon, Gavaghan, and Noble, 2011).…”
Section: Introductionmentioning
confidence: 99%
“…A substantial number of adults in the USA are living with a chronic illness. For example, 85.6 million people are living with some form of cardiovascular disease or the after effects of a stroke (1), 14.5 million people have a history of cancer or are currently living with cancer (2), and 21.0 million people have been diagnosed with diabetes (3). The diagnosis of a chronic illness can be a major stressor, one with which both the patient and their social network must learn to cope with for a long period of time.…”
mentioning
confidence: 99%
“…The situation is likely exacerbated in rural areas, where diabetes incidence is about 17% higher than in urbanized regions (2). Also, compared with urban communities, rural communities continue to have higher rates of coronary heart disease (3), the foremost cause of death for adults in the United States (4).…”
mentioning
confidence: 99%